A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC 742460) in Children With Relapsed/Refractory Solid Tumors

Trial Profile

A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC 742460) in Children With Relapsed/Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs Cixutumumab (Primary)
  • Indications CNS cancer; Ewing's sarcoma; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 30 Apr 2008 New trial centres added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top